Tigecycline - Resistant Pathogen Program

•                 Phase 3, open-label, noncomparative study of Tigecycline's  (Wyeth) efficacy in treating bactermia secondary to

                           non-Pseudomonal gram negative bacteria and side-effects.

•                 Phase 3, multicenter, double-blinded, randomized (3:1)  comparative study of Tigecycline's  (Wyeth) efficacy in treating

                           bacteremia secondary to MRSA and/or VRE and side-effects versus Linezolid.

Please contact Heather McNutt (daytime #6476) or Dr. Munasinghe (nighttime #3681) if you have a patient with MRSA, VRE, or gram negative bacteremia.

ACUITY Trial

•             Randomized comparison of Angiomax (bivalirudin) versus UFH in patients undergoing early invasive management for

                            acute coronary syndromes without ST-segment elevation/

Please contact Heather McNutt (daytime-#6476) or Dr. Mahmood (anytime #11586) if you have a patient with a diagnosis consistent with unstable angina or NSTEMI.